Annals of Nuclear Medicine

, Volume 33, Issue 1, pp 55–60 | Cite as

Clinical feasibility of early scanning after administration of 68Ga-DOTATOC

  • Yuji NakamotoEmail author
  • Takayoshi Ishimori
  • Kohei Sano
  • Yoichi Shimizu
  • Kaori Togashi
Original Article



Positron emission tomography (PET)/computed tomography (CT) using 68Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid-d-Phe1-Tyr3-octreotide (DOTATOC) is usually performed about 1-h post-injection; however, because of rapid blood clearance, the waiting time for scanning could possibly be shortened without affecting diagnostic performance. The purpose of this study was to investigate the feasibility of early scanning at 30 min post-injection.


Thirty-eight patients who underwent DOTATOC-PET/CT were analyzed. After administration of 68Ga-DOTATOC, data acquisition was performed twice, at 30-min and 60-min post-injection. The number of known or suspected pathological lesions, and quantitative values of those lesions and physiological uptake were compared. SUVmax, SUVpeak, metabolic tumor volume (MTV), and total lesion uptake (TLU) were calculated as quantitative values of the pathological lesions.


A total of 125 known or suspected pathological lesions were found at both timepoints, with no differences between the two datasets. The SUVmax, SUVpeak, MTV, and TLU were highly reproducible, with Spearman’s ρ of 0.983, 0.986, 0.918, and 0.981, respectively. The average percent differences (%DIFFave) defined as the differences of the values divided by the value at 1-h post-injection were 11.1% for SUVmax, 8.5% for SUVpeak, 15.1% for MTV, and 20.6% for TLU. Physiological uptake in the two datasets was closely comparable in the pituitary gland (Spearman’s ρ = 0.954, %DIFFave = 11.0%), liver (0.989, 3.9%), spleen (0.970, 6.3%), adrenal glands (0.879, 13.0%), and pancreatic uncus (0.946, 12.7%).


The diagnostic performance of visual interpretation should be comparable between DOTATOC-PET/CT images obtained at 30-min and 60-min post-injection. Some differences between quantitative values may exist; however, they appear to be minimal.


PET DOTATOC Waiting time 



This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (16K10346).

Compliance with ethical standards

Conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


  1. 1.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: 68 Ga-DOTA0,Tyr3-octreotide versus 68 Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging. 2013;40:364–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58:756–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601.CrossRefPubMedGoogle Scholar
  5. 5.
    Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, et al. Quantitative and qualitative intrapatient comparison of 68 Ga-DOTATOC and 68 Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55:204–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Nakamoto Y, Ishimori T, Sano K, Temma T, Ueda M, Saji H, et al. Clinical efficacy of dual-phase scanning using (68)Ga-DOTATOC-PET/CT in the detection of neuroendocrine tumours. Clin Radiol. 2016;71:1069.e1-5.CrossRefPubMedGoogle Scholar
  7. 7.
    Dirisamer A, Halpern BS, Schima W, Heinisch M, Wolf F, Beheshti M, et al. Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol. 2008;10:335–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Miyake KK, Nakamoto Y, Togashi K. Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: clinical value of early delayed scanning. Ann Nucl Med. 2012;26:492–500.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2018

Authors and Affiliations

  1. 1.Department of Diagnostic Imaging and Nuclear MedicineKyoto University Graduate School of MedicineKyotoJapan
  2. 2.Laboratory of Biophysical ChemistryKobe Pharmaceutical UniversityKobeJapan

Personalised recommendations